The Association of Biotechnology Companies BioForum launches the #polishbiotech online database as the largest association of biotech companies in Poland.
We are the first point of contact for entrepreneurs in the biotechnology industry and we constantly support the Polish biotechnology community 👩🔬 👨🔬
SIGN UP HERE 👇👇👇
"*" indicates required fields
Captor Therapeutics S.A.
+ business areaBioPharma R&D+Services
+ annual revenue
2021 – 3,990,000 PLN
2022 – 9,160,000 PLN
2023 – 13,200,000 PLN
2024 – 15,830,000 PLN
+ workforce (estimated if not reported)
2021 – 98
2022 – 111
2023 – 105
2024 – 91
+ depreciation & amortization
2019 – 732,000
2020 – 3,110,000
2021 – 2,920,000
2022 – 2,497,000
2023 – 5,784,000
2024 – 309,000
Captor Therapeutics is a biopharmaceutical company leveraging Targeted Protein Degradation (TPD) technology to discover and develop breakthrough therapeutics for high unmet medical needs.
TPD revolutionizes drug development by targeting "undruggable" molecular targets and providing new treatment options for diseases with unmet medical needs. Captor, based in Basel, Switzerland, and Wroclaw, Poland, develops therapeutics for severe conditions like cancer and autoimmune diseases.